Claritas Pharmaceuticals, Inc. (CLAZF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 100.0% |
| 2020 | -3.27 Million USD | 87.34% |
| 2019 | -25.87 Million USD | -463.99% |
| 2018 | -4.58 Million USD | 68.36% |
| 2017 | -14.49 Million USD | -20.87% |
| 2016 | -11.99 Million USD | -754.42% |
| 2015 | -1.4 Million USD | -973.44% |
| 2014 | -130.79 Thousand USD | 99.04% |
| 2013 | -13.63 Million USD | 41.03% |
| 2012 | -23.12 Million USD | -212.15% |
| 2011 | -7.4 Million USD | -4.46% |
| 2010 | -7.09 Million USD | -135.14% |
| 2009 | -3.01 Million USD | -143.02% |
| 2008 | -1.24 Million USD | 2.32% |
| 2007 | -1.27 Million USD | -226.82% |
| 2006 | -388.78 Thousand USD | -121.5% |
| 2005 | -175.52 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 FY | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2021 Q1 | -160.18 Thousand USD | 95.02% |
| 2021 Q4 | - USD | 100.0% |
| 2021 FY | - USD | 100.0% |
| 2021 Q2 | -544.34 Thousand USD | -239.82% |
| 2021 Q3 | -510.5 Thousand USD | 6.22% |
| 2020 FY | -3.27 Million USD | 87.34% |
| 2020 Q3 | 210 Thousand USD | 157.07% |
| 2020 Q4 | -3.21 Million USD | -1630.48% |
| 2020 Q1 | 1.7 Million USD | 215.04% |
| 2020 Q2 | -368 Thousand USD | -121.57% |
| 2019 FY | -25.87 Million USD | -463.99% |
| 2019 Q1 | -6.39 Million USD | 34.04% |
| 2019 Q2 | -11.07 Million USD | -73.33% |
| 2019 Q3 | -1.54 Million USD | 86.06% |
| 2019 Q4 | -1.48 Million USD | 3.95% |
| 2018 Q2 | -2.18 Million USD | 65.19% |
| 2018 Q1 | -6.27 Million USD | -996.33% |
| 2018 Q3 | 10.26 Million USD | 570.0% |
| 2018 FY | -4.58 Million USD | 68.36% |
| 2018 Q4 | -9.69 Million USD | -194.44% |
| 2017 Q3 | -816 Thousand USD | 57.37% |
| 2017 Q1 | -1.61 Million USD | 86.37% |
| 2017 FY | -14.49 Million USD | -20.87% |
| 2017 Q4 | -572 Thousand USD | 29.9% |
| 2017 Q2 | -1.91 Million USD | -18.66% |
| 2016 Q1 | -549 Thousand USD | -3765.38% |
| 2016 Q2 | -1.13 Million USD | -105.83% |
| 2016 FY | -11.99 Million USD | -754.42% |
| 2016 Q3 | -625 Thousand USD | 44.69% |
| 2016 Q4 | -11.83 Million USD | -1793.74% |
| 2015 FY | -1.4 Million USD | -973.44% |
| 2015 Q1 | -9606.00 USD | 85.1% |
| 2015 Q2 | -66.27 Thousand USD | -589.9% |
| 2015 Q3 | -8376.00 USD | 87.36% |
| 2015 Q4 | -14.2 Thousand USD | -69.57% |
| 2014 Q1 | -85.32 Thousand USD | -101.69% |
| 2014 Q4 | -64.44 Thousand USD | -216.68% |
| 2014 FY | -130.79 Thousand USD | 99.04% |
| 2014 Q3 | 55.23 Thousand USD | 252.36% |
| 2014 Q2 | -36.25 Thousand USD | 57.51% |
| 2013 Q1 | -1.17 Million USD | 93.82% |
| 2013 FY | -13.63 Million USD | 41.03% |
| 2013 Q4 | 5.04 Million USD | 161.11% |
| 2013 Q3 | -8.25 Million USD | 10.72% |
| 2013 Q2 | -9.25 Million USD | -688.66% |
| 2012 Q3 | -849.54 Thousand USD | 43.51% |
| 2012 Q1 | -1.96 Million USD | -178.15% |
| 2012 Q2 | -1.5 Million USD | 23.51% |
| 2012 FY | -23.12 Million USD | -212.15% |
| 2012 Q4 | -18.98 Million USD | -2134.27% |
| 2011 FY | -7.4 Million USD | -4.46% |
| 2011 Q4 | 2.51 Million USD | 186.77% |
| 2011 Q3 | -2.89 Million USD | 24.06% |
| 2011 Q2 | -3.81 Million USD | -102.41% |
| 2011 Q1 | -1.88 Million USD | 28.98% |
| 2010 Q1 | -1.57 Million USD | -5.74% |
| 2010 FY | -7.09 Million USD | -135.14% |
| 2010 Q4 | -2.65 Million USD | -7270.2% |
| 2010 Q3 | 37.04 Thousand USD | 101.99% |
| 2010 Q2 | -1.86 Million USD | -18.48% |
| 2009 Q4 | -1.48 Million USD | -145.92% |
| 2009 FY | -3.01 Million USD | -143.02% |
| 2009 Q1 | -84.72 Thousand USD | 50.59% |
| 2009 Q2 | -529.98 Thousand USD | -525.52% |
| 2009 Q3 | -605.12 Thousand USD | -14.18% |
| 2008 Q3 | -199.17 Thousand USD | 58.83% |
| 2008 Q1 | -416.91 Thousand USD | 15.4% |
| 2008 FY | -1.24 Million USD | 2.32% |
| 2008 Q4 | -171.47 Thousand USD | 13.91% |
| 2008 Q2 | -483.76 Thousand USD | -16.04% |
| 2007 FY | -1.27 Million USD | -226.82% |
| 2007 Q4 | -492.79 Thousand USD | -78.15% |
| 2007 Q2 | -353.62 Thousand USD | -236.67% |
| 2007 Q3 | -276.62 Thousand USD | 21.78% |
| 2007 Q1 | -105.03 Thousand USD | 44.35% |
| 2006 Q4 | -188.73 Thousand USD | -186.41% |
| 2006 Q1 | -39.67 Thousand USD | 14.31% |
| 2006 FY | -388.78 Thousand USD | -121.5% |
| 2006 Q3 | -65.89 Thousand USD | 29.09% |
| 2006 Q2 | -92.93 Thousand USD | -134.21% |
| 2005 Q2 | -45.72 Thousand USD | -134.81% |
| 2005 Q4 | -46.3 Thousand USD | 23.82% |
| 2005 FY | -175.52 Thousand USD | 0.0% |
| 2005 Q1 | -19.47 Thousand USD | 0.0% |
| 2005 Q3 | -60.78 Thousand USD | -32.94% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 100.0% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 100.0% |
| CytoDyn Inc. | -18.05 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| MultiCell Technologies, Inc. | -722.81 USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 100.0% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 100.0% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| Alpha Cognition Inc. | -9.7 Million USD | 100.0% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 100.0% |
| SQZ Biotechnologies Company | -75.82 Million USD | 100.0% |
| Resverlogix Corp. | -12.74 Million USD | 100.0% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 100.0% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 100.0% |
| Mesoblast Limited | -84.14 Million USD | 100.0% |
| GB Sciences, Inc. | -1.42 Million USD | 100.0% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 100.0% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 100.0% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 100.0% |
| ContraFect Corporation | -56.88 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 100.0% |
| BioStem Technologies, Inc. | -7.77 Million USD | 100.0% |
| LadRx Corporation | -3.82 Million USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 100.0% |
| CSL Limited | 3.7 Billion USD | 100.0% |
| Biomind Labs Inc. | -1 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.0% |
| Nascent Biotech, Inc. | -2.22 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 100.0% |
| Marizyme, Inc. | -34.08 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 100.0% |
| Zenith Capital Corp. | -8.94 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 100.0% |
| Halberd Corporation | -75.05 Thousand USD | 100.0% |
| Genus plc | 6.4 Million USD | 100.0% |
| Pharming Group N.V. | -4.87 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 100.0% |
| IMV Inc. | -38.67 Million USD | 100.0% |
| Affymax, Inc. | -15.04 Million USD | 100.0% |
| SYBLEU INC | -149.18 Thousand USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 100.0% |
| Enzolytics Inc. | -2.14 Million USD | 100.0% |
| argenx SE | -425.04 Million USD | 100.0% |
| AVAX Technologies, Inc. | 6.69 Million USD | 100.0% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 100.0% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 100.0% |
| Cell Source, Inc. | -4.32 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | -483.06 Thousand USD | 100.0% |
| Q BioMed Inc. | -3.44 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 100.0% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 100.0% |
| Rebus Holdings, Inc. | -664 Thousand USD | 100.0% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | -13.67 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 100.0% |
| ONE Bio Corp. | 13.68 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 100.0% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 100.0% |
| Kadimastem Ltd | -3.04 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 100.0% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 100.0% |
| NovAccess Global Inc. | -2.46 Million USD | 100.0% |
| Itoco Inc. | -919.14 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 100.0% |
| Qrons Inc. | -643.67 Thousand USD | 100.0% |
| Mobile Lads Corp. | -554.55 Thousand USD | 100.0% |
| Genscript Biotech Corporation | -415.79 Million USD | 100.0% |
| International Stem Cell Corporation | -663 Thousand USD | 100.0% |
| Bioxytran, Inc. | -3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -36.26 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | -735.83 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 100.0% |
| Neutra Corp. | -229.48 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 100.0% |
| PureTech Health plc | -146.19 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 100.0% |
| IXICO plc | -1.43 Million USD | 100.0% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 100.0% |
| CSL Limited | 3.81 Billion USD | 100.0% |
| Cellectis S.A. | -108.85 Million USD | 100.0% |